Fate Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
FATE Nasdaq 2834 www.fatetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Fate Therapeutics, Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan 3rd, 2025 9:01 pm
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? - Dec 12th, 2024 4:30 pm
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - Dec 9th, 2024 9:01 pm
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Dec 3rd, 2024 9:01 pm
Fate Therapeutics makes Bob Valamehr president and CEO - Dec 2nd, 2024 2:55 pm
Fate Therapeutics Announces Leadership Transition - Nov 29th, 2024 6:05 pm
Fate Therapeutics to Present at Upcoming December Investor Conferences - Nov 26th, 2024 9:01 pm
Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results - Nov 18th, 2024 5:18 pm
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - Nov 18th, 2024 1:05 pm
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - Nov 18th, 2024 1:00 pm
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Nov 15th, 2024 11:44 am
Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Nov 14th, 2024 11:43 am
FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus - Nov 13th, 2024 4:19 pm
Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates - Nov 12th, 2024 10:20 pm
Fate Therapeutics: Q3 Earnings Snapshot - Nov 12th, 2024 9:18 pm
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - Nov 12th, 2024 9:01 pm
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting - Nov 9th, 2024 6:30 pm
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting - Nov 8th, 2024 9:01 pm
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference - Sep 12th, 2024 8:01 pm
Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report? - Sep 12th, 2024 3:30 pm